SEARCH

SEARCH BY CITATION

Figure S1. Change in weekly average scores of abdominal pain/discomfort. Significant decrease in the symptom severity from the baseline was observed at each time point in the ramosetron and mebeverine groups (P < 0.001 by repeated measures anova).

Figure S2. Change in weekly average scores of urgency. Significant decrease in the symptom severity from the baseline was observed at each time point in the ramosetron and mebeverine groups (P < 0.001 by repeated measures anova).

Figure S3. Change in weekly average scores of Bristol stool form scale. Significant decrease in the stool form score from the baseline was observed at each time point in the ramosetron and mebeverine groups (P < 0.001 by repeated measures anova).

Figure S4. Change in weekly average stool frequency. Significant decrease in the stool frequency from the baseline was observed at each time point in the ramosetron and mebeverine groups (= 0.011 and 0.019 by repeated measures anova, respectively).

FilenameFormatSizeDescription
NMO_1771_sm_FigS1.tif67KSupporting info item
NMO_1771_sm_FigS2.tif64KSupporting info item
NMO_1771_sm_FigS3.tif64KSupporting info item
NMO_1771_sm_FigS4.tif63KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.